

# Massimo Brogginì

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6290165/publications.pdf>

Version: 2024-02-01

203  
papers

6,557  
citations

66234

42  
h-index

82410

72  
g-index

210  
all docs

210  
docs citations

210  
times ranked

9625  
citing authors

#	ARTICLE	IF	CITATIONS
1	LKB1: Can We Target an Hidden Target? Focus on NSCLC. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	7
2	Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy. <i>ESMO Open</i> , 2021, 6, 100034.	2.0	0
3	The Crossroads between Host Copper Metabolism and Influenza Infection. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5498.	1.8	6
4	The integrated stress response is tumorigenic and constitutes a therapeutic liability in KRAS-driven lung cancer. <i>Nature Communications</i> , 2021, 12, 4651.	5.8	22
5	LKB1 Down-Modulation by miR-17 Identifies Patients With NSCLC Having Worse Prognosis Eligible for Energy-Stress-Based Treatments. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1298-1311.	0.5	9
6	KRAS Targeting and Resistance: Anticipating the Expectable. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1239-1241.	0.5	1
7	miR-17 Epigenetic Modulation of LKB1 Expression in Tumor Cells Uncovers a New Group of Patients With Poor-Prognosis NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, e68-e70.	0.5	0
8	LKB1 Deficiency Renders NSCLC Cells Sensitive to ERK Inhibitors. <i>Journal of Thoracic Oncology</i> , 2020, 15, 360-370.	0.5	24
9	Anti-Influenza Effect of Nanosilver in a Mouse Model. <i>Vaccines</i> , 2020, 8, 679.	2.1	8
10	It's Got Too Greedy. New Therapeutic Options for Metabolic[ally] Addicted NSCLC?. <i>Cancers</i> , 2020, 12, 3223.	1.7	0
11	Glutaminase Inhibition on NSCLC Depends on Extracellular Alanine Exploitation. <i>Cells</i> , 2020, 9, 1766.	1.8	19
12	Inhibition of the Lysophosphatidylinositol Transporter ABCC1 Reduces Prostate Cancer Cell Growth and Sensitizes to Chemotherapy. <i>Cancers</i> , 2020, 12, 2022.	1.7	13
13	LKB1ness Dictates ERK Inhibitors Response in NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, e59.	0.5	2
14	Predicting the Role of DNA Polymerase $\beta$ Alone or with KRAS Mutations in Advanced NSCLC Patients Receiving Platinum-Based Chemotherapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 2438.	1.0	2
15	Establishment and Characterization of Patient-Derived Xenografts (PDXs) of Different Histology from Malignant Pleural Mesothelioma Patients. <i>Cancers</i> , 2020, 12, 3846.	1.7	5
16	Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations. <i>Frontiers in Oncology</i> , 2020, 10, 532292.	1.3	6
17	Molecular determinants of response to PI3K/akt/mTOR and KRAS pathways inhibitors in NSCLC cell lines. <i>American Journal of Cancer Research</i> , 2020, 10, 4488-4497.	1.4	0
18	Platinum Resistance in Ovarian Cancer: Role of DNA Repair. <i>Cancers</i> , 2019, 11, 119.	1.7	196

#	ARTICLE	IF	CITATIONS
19	Silver Ions as a Tool for Understanding Different Aspects of Copper Metabolism. <i>Nutrients</i> , 2019, 11, 1364.	1.7	38
20	CRISPR/Cas9 Mediated Deletion of Copper Transport Genes CTR1 and DMT1 in NSCLC Cell Line H1299. Biological and Pharmacological Consequences. <i>Cells</i> , 2019, 8, 322.	1.8	12
21	<p>Lack of Efficacy: When Opioids Do Not Achieve Analgesia from the Beginning of Treatment in Cancer Patients</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 10337-10344.	0.9	3
22	Downregulation of class II phosphoinositide 3-kinase PI3K-C2 <sup>1</sup> 2 delays cell division and potentiates the effect of docetaxel on cancer cell growth. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 472.	3.5	14
23	Exploiting Fasting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial. <i>Clinical Lung Cancer</i> , 2019, 20, e413-e417.	1.1	27
24	Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib. <i>Scientific Reports</i> , 2018, 8, 948.	1.6	19
25	PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. <i>Clinical Cancer Research</i> , 2018, 24, 120-129.	3.2	92
26	Structure-Activity Relationships of Hexahydrocyclopenta[ <i>c</i> ]quinoline Derivatives as Allosteric Inhibitors of CDK2 and EGFR. <i>ChemMedChem</i> , 2018, 13, 2627-2634.	1.6	23
27	Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 302.	3.5	27
28	Generation and characterization of MEK and ERK inhibitors- resistant non-small-cells-lung-cancer (NSCLC) cells. <i>BMC Cancer</i> , 2018, 18, 1028.	1.1	7
29	Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1692-1704.	0.5	74
30	Identification of small-molecule EGFR allosteric inhibitors by high-throughput docking. <i>Future Medicinal Chemistry</i> , 2018, 10, 1545-1553.	1.1	21
31	RELEVANT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma. <i>Clinical Lung Cancer</i> , 2018, 19, e811-e814.	1.1	15
32	RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients. <i>Oncogene</i> , 2018, 37, 6463-6476.	2.6	15
33	Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 140.	3.5	27
34	Abstract A112: RanBP9 protects cells from genotoxic stress and increased expression is predictive of worse response to platinum in NSCLC patients. , 2018, , .		0
35	Abstract LB-245: Multiple DNA-damage response pathways are modulated by RANBP9 protein in NSCLC. , 2018, , .		0
36	Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models. <i>Translational Oncology</i> , 2017, 10, 153-157.	1.7	9

#	ARTICLE	IF	CITATIONS
37	Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts. <i>Molecular Cancer</i> , 2017, 16, 97.	7.9	15
38	Probing an Allosteric Pocket of CDK2 with Small Molecules. <i>ChemMedChem</i> , 2017, 12, 33-41.	1.6	21
39	P2.02-065 RanBP9 is a Novel Prognostic and Predictive Biomarker for NSCLC and Affects Cellular Response to Cisplatin and PARP Inhibitors. <i>Journal of Thoracic Oncology</i> , 2017, 12, S2123-S2124.	0.5	0
40	Correlation between clinical outcomes of patients treated within the tailor trial and next-generation sequencing (NGS) results: Analysis of genes associated to KRAS mutations. <i>Annals of Oncology</i> , 2017, 28, ii61.	0.6	1
41	Co-existence of KRAS and LKB1 mutation as predictor of resistance to Erlotinib: Customized next-generation sequencing (NGS) of TAILOR trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20631-e20631.	0.8	0
42	Abstract 2352: Effect of inhibition of cell cycle versus transcription cyclin-dependent kinases (CDKs) in ovarian cancer cells. , 2017, , .		0
43	Abstract 174: Preclinical activity of new liposomal formulation of doxorubicin (TLD-1). , 2017, , .		0
44	Abstract 760: Detection of EGFR T790M mutation by ddPCR in untreated NSCLC patients: Correlation with clinical outcome. , 2017, , .		0
45	Abstract 3739: Comparison of technologies forEGFRanalysis within a subset of a randomized clinical trial. , 2017, , .		2
46	Abstract 508: DNA repair status in a patient derived ovarian cancer xenobank. , 2017, , .		1
47	Characterization of MTAP Gene Expression in Breast Cancer Patients and Cell Lines. <i>PLoS ONE</i> , 2016, 11, e0145647.	1.1	18
48	The 5â€™UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs. <i>Scientific Reports</i> , 2016, 6, 39217.	1.6	3
49	Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer?. <i>Cancer Treatment Reviews</i> , 2016, 48, 8-19.	3.4	26
50	G48A, a New KRAS Mutation Found in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1170-1175.	0.5	5
51	In vivo effect of copper status on cisplatin-induced nephrotoxicity. <i>BioMetals</i> , 2016, 29, 841-849.	1.8	7
52	Comparative metabolomics profiling of isogenic KRAS wild type and mutant NSCLC cells in vitro and in vivo. <i>Scientific Reports</i> , 2016, 6, 28398.	1.6	29
53	Activity of Pan-Class I Isoform PI3K/mTOR Inhibitor PF-05212384 in Combination with Crizotinib in Ovarian Cancer Xenografts and PDX. <i>Translational Oncology</i> , 2016, 9, 458-465.	1.7	9
54	â††Np73beta induces caveolin-1 in human non-small cell lung cancer cell line H1299. <i>Tumor Biology</i> , 2016, 37, 2015-2021.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Class II phosphoinositide 3-kinase C2 <sup>1</sup> 2 regulates a novel signaling pathway involved in breast cancer progression. <i>Oncotarget</i> , 2016, 7, 18325-18345.	0.8	25
56	Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS. <i>Oncotarget</i> , 2016, 7, 51462-51472.	0.8	21
57	Abstract 226: PI3K pathway inhibition induces a different metabolic response in NSCLC cells harboring WT and G12C mutant KRAS. , 2016, , .		0
58	Abstract 380: The dual PI3K/MTOR inhibitor PQR309 is active in mature B cell lymphoma cell lines bearing resistance to the PI3K-delta inhibitor idelalisib and specific gene expression features. , 2016, , .		0
59	Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR). <i>Scientific Reports</i> , 2015, 5, 16331.	1.6	10
60	Germ Cell Tumors Overexpress the Candidate Therapeutic target Cyclin B1 Independently of p53 function. <i>International Journal of Biological Markers</i> , 2015, 30, 275-281.	0.7	3
61	<i>KRAS</i> mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy. <i>Oncotarget</i> , 2015, 6, 34014-34022.	0.8	68
62	EGFR mutations and EGFR tyrosine kinase inhibitors. <i>Lancet Oncology</i> , The, 2015, 16, 746-748.	5.1	3
63	Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial. <i>Annals of Oncology</i> , 2015, 26, 2079-2084.	0.6	42
64	Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors. <i>Annals of Oncology</i> , 2015, 26, 838-847.	0.6	21
65	Abstract 2652: Pre-clinical activity and mechanism of action of the novel dual PI3K/mTOR inhibitor PQR309 in B-cell lymphomas. , 2015, , .		1
66	Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells. <i>Oncotarget</i> , 2015, 6, 30072-30087.	0.8	43
67	Abstract 3500: Combinations of ARQ087 with chemotherapeutic agents are safe and show a striking antitumor activity in different xenograft models. , 2015, , .		0
68	Abstract 1654: The small molecule YK-4-279 shows anti-lymphoma activity in pre-clinical models. , 2015, , .		0
69	Chemotherapy versus tyrosine kinase inhibitor in EGFR unselected population advanced non-small cell lung cancer still matter of debate?-An update incorporating the DELTA trial data. <i>Journal of Thoracic Disease</i> , 2015, 7, 224-6.	0.6	2
70	Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells. <i>Oncotarget</i> , 2014, 5, 4722-4731.	0.8	80
71	Direct but not indirect co-culture with osteogenically differentiated human bone marrow stromal cells increases RANKL/OPG ratio in human breast cancer cells generating bone metastases. <i>Molecular Cancer</i> , 2014, 13, 238.	7.9	24
72	Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2. <i>Cell Cycle</i> , 2014, 13, 2296-2305.	1.3	48

#	ARTICLE	IF	CITATIONS
73	DRAGO (KIAA0247), a New DNA Damage-Responsive, p53-Inducible Gene That Cooperates With p53 as Oncosuppressor. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju053.	3.0	19
74	Brassinin and its derivatives as potential anticancer agents. <i>Toxicology in Vitro</i> , 2014, 28, 909-915.	1.1	31
75	Benzylidenetetralones, cyclic chalcone analogues, induce cell cycle arrest and apoptosis in HCT116 colorectal cancer cells. <i>Tumor Biology</i> , 2014, 35, 9967-9975.	0.8	27
76	Genetic markers for prediction of treatment outcomes in ovarian cancer. <i>Pharmacogenomics Journal</i> , 2014, 14, 401-410.	0.9	16
77	Across the Universe of K-Ras Mutations in Non-Small-Cell-Lung Cancer. <i>Current Pharmaceutical Design</i> , 2014, 20, 3933-3943.	0.9	27
78	Abstract 4406: Role of KRAS in modulating the metabolomic profile and the response of NSCLC cells to PI3K/mTOR and AMPK interfering agents. , 2014, , .		0
79	Abstract 2766: Inhibition of Chk1 and Wee1 as a new therapeutic approach in Mantle Cell Lymphoma. , 2014, , .		0
80	Abstract 3760: Role of epithelial to mesenchymal transition in response to cisplatin in patient-derived ovarian carcinomas. , 2014, , .		0
81	Abstract 803: A vertical combination strategy hitting multiple steps along the MAPK cascade: Molecular mechanisms of action and putative genetic determinants of synergism. , 2014, , .		0
82	The Novel PI3K/mTOR Dual Inhibitor PQR309 in Pre-Clinical Lymphoma Models: Demonstration of Anti-Tumor Activity As Single Agent and in Combination and Identification of Gene Expression Signatures Associated with Response. <i>Blood</i> , 2014, 124, 1782-1782.	0.6	1
83	Abstract A54: Studies on the molecular mechanisms responsible for cisplatin resistance associated to KRAS G12C mutation in NSCLC. , 2014, , .		0
84	Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. <i>Lancet Oncology</i> , The, 2013, 14, 981-988.	5.1	472
85	Revisiting ovarian cancer preclinical models: Implications for a better management of the disease. <i>Cancer Treatment Reviews</i> , 2013, 39, 561-568.	3.4	24
86	To Target or Not to Target, That Is the Question. <i>Journal of Clinical Oncology</i> , 2013, 31, 1254-1254.	0.8	3
87	Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET- <sup>+</sup> Letter. <i>Clinical Cancer Research</i> , 2013, 19, 4290-4290.	3.2	12
88	Seminars in clinical pharmacology: an introduction to MET inhibitors for the medical oncologist. <i>Annals of Oncology</i> , 2013, 24, 14-20.	0.6	34
89	Zebularine partially reverses GST methylation in prostate cancer cells and restores sensitivity to the DNA minor groove binder brostallicin. <i>Epigenetics</i> , 2013, 8, 656-665.	1.3	26
90	DNA-damage response gene polymorphisms and therapeutic outcomes in ovarian cancer. <i>Pharmacogenomics Journal</i> , 2013, 13, 159-172.	0.9	16

#	ARTICLE	IF	CITATIONS
91	Non-hepatic tumors change the activity of genes encoding copper trafficking proteins in the liver. <i>Cancer Biology and Therapy</i> , 2013, 14, 614-624.	1.5	16
92	Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer. <i>Cancer Management and Research</i> , 2013, 5, 15.	0.9	4
93	Triple Negative Breast Cancers Have a Reduced Expression of DNA Repair Genes. <i>PLoS ONE</i> , 2013, 8, e66243.	1.1	35
94	Combination of the c-Met Inhibitor Tivantinib and Zoledronic Acid Prevents Tumor Bone Engraftment and Inhibits Progression of Established Bone Metastases in a Breast Xenograft Model. <i>PLoS ONE</i> , 2013, 8, e79101.	1.1	16
95	Abstract 792: DRAGO (KIAA0247), a new p53-regulated antioncogene.. , 2013, , .		0
96	ALDH enzymatic activity and CD133 positivity and response to chemotherapy in ovarian cancer patients. <i>American Journal of Cancer Research</i> , 2013, 3, 221-9.	1.4	11
97	RAS/RAF/MEK Inhibitors in Oncology. <i>Current Medicinal Chemistry</i> , 2012, 19, 1164-1176.	1.2	54
98	Combined inhibition of Chk1 and Wee1: In vitro synergistic effect translates to tumor growth inhibition in vivo. <i>Cell Cycle</i> , 2012, 11, 2507-2517.	1.3	110
99	Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype. <i>Cell Cycle</i> , 2012, 11, 1966-1976.	1.3	43
100	Breast Cancerâ€œDerived Bone Metastasis Can Be Effectively Reduced through Specific c-MET Inhibitor Tivantinib (ARQ 197) and shRNA c-MET Knockdown. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 214-223.	1.9	58
101	Epithelialâ€œmesenchymal transition and breast cancer: Role, molecular mechanisms and clinical impact. <i>Cancer Treatment Reviews</i> , 2012, 38, 689-697.	3.4	235
102	Serum depletion of holo-ceruloplasmin induced by silver ions in vivo reduces uptake of cisplatin. <i>Journal of Inorganic Biochemistry</i> , 2012, 116, 88-96.	1.5	19
103	TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA7501-LBA7501.	0.8	26
104	TAILOR: Phase III trial comparing erlotinib with docetaxel in the second-line treatment of NSCLC patients with wild-type (wt) EGFR.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA7501-LBA7501.	0.8	13
105	KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer. <i>American Journal of Cancer Research</i> , 2012, 2, 298-308.	1.4	7
106	New Omics Information for Clinical Trial Utility in the Primary Setting. <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 128-133.	0.9	4
107	Experimental switching of copper status in laboratory rodents. <i>Journal of Trace Elements in Medicine and Biology</i> , 2011, 25, 27-35.	1.5	15
108	Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. <i>Annals of Oncology</i> , 2011, 22, 235-237.	0.6	170



#	ARTICLE	IF	CITATIONS
109	Combination of PI3K/mTOR Inhibitors: Antitumor Activity and Molecular Correlates. <i>Cancer Research</i> , 2011, 71, 4573-4584.	0.4	68
110	Spectrum of Cellular Responses to Pyriplatin, a Monofunctional Cationic Antineoplastic Platinum(II) Compound, in Human Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1709-1719.	1.9	67
111	Abstract B77: KRAS mutational status impact progression-free survival of patients treated with platinum-based chemotherapy in NSCLC. , 2011, , .		1
112	Role of Chk1 in the differentiation program of hematopoietic stem cells. <i>Cellular and Molecular Life Sciences</i> , 2010, 67, 1713-1722.	2.4	6
113	Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts. <i>Gynecologic Oncology</i> , 2010, 118, 182-188.	0.6	54
114	A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate. <i>British Journal of Cancer</i> , 2010, 102, 104-114.	2.9	54
115	Preclinical Colorectal Cancer Chemopreventive Efficacy and p53-Modulating Activity of 3,4,5,6-Triethoxyflavonol, a Quercetin Analogue. <i>Cancer Prevention Research</i> , 2010, 3, 929-939.	0.7	22
116	Role of Cetuximab in the Treatment of Patients With NSCLC: Are We Throwing Out the Baby With the Bath Water?. <i>Journal of Clinical Oncology</i> , 2010, 28, e467-e467.	0.8	1
117	PI3K/AKT/mTOR Inhibitors In Ovarian Cancer. <i>Current Medicinal Chemistry</i> , 2010, 17, 4433-4447.	1.2	41
118	Down-regulation of the Nucleotide Excision Repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells. <i>Molecular Cancer</i> , 2010, 9, 259.	7.9	34
119	Role of Glutathione Transferases in the Mechanism of Brostallicin Activation. <i>Biochemistry</i> , 2010, 49, 226-235.	1.2	16
120	Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and $\beta$ -catenin/Wnt pathways. <i>European Journal of Cancer</i> , 2010, 46, 1679-1691.	1.3	85
121	HtrA2 enhances the apoptotic functions of p73 on bax. <i>Cell Death and Differentiation</i> , 2008, 15, 849-858.	5.0	27
122	Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancer. <i>Oncogene</i> , 2008, 27, 1805-1811.	2.6	54
123	Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer. <i>European Journal of Cancer</i> , 2008, 44, 131-141.	1.3	28
124	$^{125}$ I-Np63 expression is associated with poor survival in ovarian cancer. <i>Annals of Oncology</i> , 2008, 19, 501-507.	0.6	50
125	Analysis of Gene Expression in Early-Stage Ovarian Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 7850-7860.	3.2	43
126	Checkpoint Kinase 1 Down-Regulation by an Inducible Small Interfering RNA Expression System Sensitized In vivo Tumors to Treatment with 5-Fluorouracil. <i>Clinical Cancer Research</i> , 2008, 14, 5131-5141.	3.2	42



#	ARTICLE	IF	CITATIONS
127	Phospholipase C $\beta$ 1 Is Required for Metastasis Development and Progression. <i>Cancer Research</i> , 2008, 68, 10187-10196.	0.4	135
128	KCNA1 and TRPC6 ion channels and NHE1 exchanger operate the biological outcome of HGF/scatter factor in renal tubular cells. <i>Growth Factors</i> , 2007, 25, 382-391.	0.5	22
129	p73: A chiaroscuro gene in cancer. <i>European Journal of Cancer</i> , 2007, 43, 1361-1372.	1.3	37
130	Cancer-derived p53 mutants suppress p53-target gene expression—potential mechanism for gain of function of mutant p53. <i>Nucleic Acids Research</i> , 2007, 35, 2093-2104.	6.5	123
131	Oct-4 Expression in Adult Human Differentiated Cells Challenges Its Role as a Pure Stem Cell Marker. <i>Stem Cells</i> , 2007, 25, 1675-1680.	1.4	151
132	In vivo evaluation of the role of DNp73 $\Delta$ protein in regulating the p53-dependent apoptotic pathway after treatment with cytotoxic drugs. <i>International Journal of Cancer</i> , 2007, 120, 506-513.	2.3	12
133	Preliminary safety evaluation of the putative cancer chemopreventive agent tricetin, a naturally occurring flavone. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 1-6.	1.1	57
134	Questioning the oncogenic role of p73 $\Delta$ in different cell lines expressing p53 or not. <i>Cancer Biology and Therapy</i> , 2006, 5, 794-803.	1.5	9
135	Effects of inducible overexpression of DNp73 $\Delta$ on cancer cell growth and response to treatment in vitro and in vivo. <i>Cell Death and Differentiation</i> , 2005, 12, 805-814.	5.0	18
136	PRL-3 Phosphatase Is Implicated in Ovarian Cancer Growth. <i>Clinical Cancer Research</i> , 2005, 11, 6835-6839.	3.2	134
137	Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 715-725.	1.9	27
138	Evaluation of the Combined Effect of p53 Codon 72 Polymorphism and Hotspot Mutations in Response to Anticancer Drugs. <i>Clinical Cancer Research</i> , 2005, 11, 4348-4356.	3.2	57
139	Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway by Inositol Pentakisphosphate Results in Antiangiogenic and Antitumor Effects. <i>Cancer Research</i> , 2005, 65, 8339-8349.	0.4	126
140	DNA mirror groove-binding agents. <i>Drugs of the Future</i> , 2005, 30, 301.	0.0	2
141	Chk1, but not Chk2, is Involved in the Cellular Response to DNA Damaging Agents: Differential Activity in Cells Expressing, or not, p53. <i>Cell Cycle</i> , 2004, 3, 1175-1179.	1.3	68
142	Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway. <i>Oncogene</i> , 2004, 23, 1754-1765.	2.6	89
143	Improving the selectivity of cancer treatments by interfering with cell response pathways. <i>European Journal of Cancer</i> , 2004, 40, 2550-2559.	1.3	25
144	Brostallicin: a new concept in minor groove DNA binder development. <i>Anti-Cancer Drugs</i> , 2004, 15, 1-6.	0.7	30

#	ARTICLE	IF	CITATIONS
145	Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing or not p53. <i>Cell Cycle</i> , 2004, 3, 1177-81.	1.3	35
146	Effect of Aplidin in acute lymphoblastic leukaemia cells. <i>British Journal of Cancer</i> , 2003, 89, 763-773.	2.9	52
147	Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. <i>Leukemia</i> , 2003, 17, 52-59.	3.3	142
148	DNA damage induces transcriptional activation of p73 by removing C-EBP $\beta$ repression on E2F1. <i>Nucleic Acids Research</i> , 2003, 31, 6624-6632.	6.5	29
149	Characterization of the 5'flanking region of the human Chk1 gene: identification of E2F1 functional sites. <i>Cell Cycle</i> , 2003, 2, 604-9.	1.3	23
150	Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin. <i>Clinical Cancer Research</i> , 2003, 9, 5402-8.	3.2	22
151	Genetic alterations in ovarian cancer cells that might account for sensitivity to chemotherapy in patients. <i>International Review of Cytology</i> , 2002, 219, 157-198.	6.2	8
152	Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione. <i>Cancer Research</i> , 2002, 62, 2332-6.	0.4	45
153	Cisplatinum and Taxol Induce Different Patterns of p53 Phosphorylation. <i>Neoplasia</i> , 2001, 3, 10-16.	2.3	73
154	Development of distamycin-related DNA binding anticancer drugs. <i>Expert Opinion on Investigational Drugs</i> , 2001, 10, 1703-1714.	1.9	35
155	p73 overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis. <i>Oncogene</i> , 2001, 20, 7293-7300.	2.6	51
156	DNA Damage Induces p53-dependent Down-regulation of hCHK1. <i>Journal of Biological Chemistry</i> , 2001, 276, 10641-10645.	1.6	17
157	Novel functional PI 3-kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines. <i>FASEB Journal</i> , 2000, 14, 1179-1187.	0.2	73
158	Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 6780-6784.	3.3	186
159	Driving p53 Response to Bax Activation Greatly Enhances Sensitivity to Taxol by Inducing Massive Apoptosis. <i>Neoplasia</i> , 2000, 2, 202-207.	2.3	22
160	Extranodal Marginal Zone B-Cell Lymphoma Genotyping byAlu $\beta$ Polymerase Chain Reaction. <i>Leukemia and Lymphoma</i> , 2000, 38, 605-610.	0.6	2
161	Allelic expression of p73 in human ovarian cancers. <i>Annals of Oncology</i> , 1999, 10, 949-953.	0.6	12
162	Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents. <i>British Journal of Cancer</i> , 1999, 80, 338-343.	2.9	39

#	ARTICLE	IF	CITATIONS
163	Î±-Bromoacryloyl derivative of distamycin A (PNU 151807): a new non-covalent minor groove DNA binder with antineoplastic activity. <i>British Journal of Cancer</i> , 1999, 80, 991-997.	2.9	20
164	P53-independent caspase-mediated apoptosis in human leukaemic cells is induced by a DNA minor groove binder with antineoplastic activity. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 1999, 4, 39-45.	2.2	11
165	CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers. , 1999, 26, 176-180.		82
166	Inactivation of p53 in a Human Ovarian Cancer Cell Line Increases the Sensitivity to Paclitaxel by Inducing G2/M Arrest and Apoptosis. <i>Experimental Cell Research</i> , 1998, 241, 96-101.	1.2	81
167	DNA-topoisomerase I activity and content in epithelial ovarian cancer. <i>Annals of Oncology</i> , 1998, 9, 313-318.	0.6	15
168	hMLH1 and hMSH2 expression and BAX frameshift mutations in ovarian cancer cell lines and tumors. <i>Carcinogenesis</i> , 1998, 19, 691-694.	1.3	14
169	Expression of Genes of Potential Importance in the Response to Chemotherapy and DNA Repair in Patients with Ovarian Cancer. <i>Gynecologic Oncology</i> , 1997, 65, 130-137.	0.6	53
170	Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin: Possible role of p53. , 1997, 72, 155-159.		21
171	Changes in Cyclins and Cyclin-Dependent Kinases Induced by DNA Damaging Agents in a Human Ovarian Cancer Cell Line Expressing Mutated or Wild-Type P53. <i>Experimental Cell Research</i> , 1996, 227, 380-385.	1.2	14
172	p53 Regulates the Minimal Promoter of the Human Topoisomerase II $\alpha$ Gene. <i>Nucleic Acids Research</i> , 1996, 24, 4464-4470.	6.5	83
173	Characterization of a protein recognizing minor groove binders-damaged DNA. <i>Nucleic Acids Research</i> , 1996, 24, 4227-4233.	6.5	5
174	Different vimentin expression in two clones derived from a human colocal carcinoma cell line (LoVo) showing different sensitivity to doxorubicin. <i>British Journal of Cancer</i> , 1995, 71, 505-511.	2.9	18
175	DNA sequence-specific adenine alkylation by the novel antitumor drug tallimustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin. <i>Nucleic Acids Research</i> , 1995, 23, 81-87.	6.5	92
176	Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53. <i>Nucleic Acids Research</i> , 1994, 22, 1012-1017.	6.5	52
177	L1210 cells selected for resistance to methoxymorpholinyl doxorubicin appear specifically resistant to this class of morpholinyl derivatives. <i>British Journal of Cancer</i> , 1994, 69, 315-319.	2.9	10
178	Establishment of L1210 leukemia cells resistant to the distamycin-a derivative (FCE 24517): Characterization and cross-resistance studies. <i>International Journal of Cancer</i> , 1993, 53, 308-314.	2.3	18
179	Characterisation of a LoVo subline resistant to a benzoyl mustard derivative of distamycin A (FCE) Tj ETQq1 1 0.784314 rgBT <sub>g</sub> /Overlook	2.9	
180	Differential inhibition of the DNA binding of transcription factors NF $\kappa$ B and OTF-1 by nitrogen mustard and quinacrine mustard: transcriptional implications. <i>Carcinogenesis</i> , 1993, 14, 1963-1967.	1.3	13

#	ARTICLE	IF	CITATIONS
181	Sequence and Gene-Specific Drugs. , 1992, , 5-11.		3
182	Cis dichlorodiammine platinum induced DNA interstrand cross-links in primary cultures of human ovarian cancer. <i>British Journal of Cancer</i> , 1991, 64, 288-292.	2.9	8
183	The inhibition of supercoiling activity of DNA gyrase from <i>Micrococcus luteus</i> caused by rifloxacin (MF 934) and MF 961. <i>Journal of Antimicrobial Chemotherapy</i> , 1991, 27, 687-689.	1.3	1
184	DNA damage and sequence specificity of DNA binding of the new anti-cancer agent 1,4-bis(2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis maleate). <i>British Journal of Cancer</i> , 1990, 61, 285-289.	2.9	8
185	Distamycins inhibit the binding of OTF-1 and NFE-1 transactors to their conserved DNA elements. <i>Nucleic Acids Research</i> , 1989, 17, 1051-1059.	6.5	99
186	DNA interstrand cross-links induced by cis-dichlorodiammine platinum in ovarian cancer cells growing in primary culture. <i>Biochemical Pharmacology</i> , 1988, 37, 1835-1836.	2.0	0
187	Early DNA damage induced in cells exposed to N10-propargyl 5,8-dideazafolic acid (CB 3717) or methotrexate. <i>Biochemical Pharmacology</i> , 1988, 37, 1875-1876.	2.0	3
188	Intracellular doxorubicin concentrations and drug-induced DNA damage in a human colon adenocarcinoma cell line and in a drug-resistant subline. <i>Biochemical Pharmacology</i> , 1988, 37, 4423-4431.	2.0	22
189	Comparison between VP 16 and VM 26 in Lewis lung carcinoma of the mouse. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1986, 22, 173-179.	0.9	18
190	In vivo studies with the novel anticancer agent mitozolomide (NSC 353451) on Lewis lung carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1986, 16, 125-8.	1.1	7
191	Tubulo-interstitial lesions mediate renal damage in adriamycin glomerulopathy. <i>Kidney International</i> , 1986, 30, 488-496.	2.6	158
192	Horseradish peroxidase/hydrogen peroxide-catalyzed oxidation of VP16-213. Identification of a new metabolite. <i>Chemico-Biological Interactions</i> , 1985, 55, 215-224.	1.7	10
193	Biochemical studies on the ability of pentamethylmelamine to interact in vivo with DNA and proteins in a sensitive murine ovarian reticular cell sarcoma. <i>Biochemical Pharmacology</i> , 1984, 33, 2715-2722.	2.0	2
194	Central side effects of pentamethylmelamine: Biochemical and behavioural studies. <i>Biochemical Pharmacology</i> , 1984, 33, 4011-4015.	2.0	1
195	Flow-cytometric analysis of DNA distribution after VP16-213 treatment of Lewis lung carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1983, 10, 208-11.	1.1	16
196	Subcellular distribution of adriamycin in the liver and tumor of 3LL-bearing mice. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1983, 19, 419-426.	0.9	5
197	Routes of elimination of hexamethylmelamine and pentamethylmelamine in the rat. <i>Xenobiotica</i> , 1982, 12, 315-321.	0.5	5
198	Studies of the mode of action of antitumour triazines and triazinesâ€™III. Metabolism studies on hexamethylmelamine. <i>Biochemical Pharmacology</i> , 1982, 31, 625-631.	2.0	14

#	ARTICLE	IF	CITATIONS
199	Pharmacokinetics of VP16-213 in Lewis lung carcinoma bearing mice. <i>Cancer Chemotherapy and Pharmacology</i> , 1982, 7, 127-31.	1.1	26
200	Adriamycin distribution in plasma and blood cells of cancer patients with altered hematocrit. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1981, 17, 1089-1096.	0.9	9
201	Diferential adriamycin® istribution to blood components. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 1981, 6, 115-122.	0.6	13
202	Influence of tumor on adriamycin concentration in blood cells. <i>Cancer Chemotherapy and Pharmacology</i> , 1980, 4, 209-12.	1.1	13
203	Importance of the presence of necrosis in studying drug distribution within tumor tissue. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 1977, 2, 63-67.	0.6	8